Synbody Biotechnology
Latest round
- Seed
Last raised
- Mar 2012
Total raised
- $0.8M
Investors
- 1
About Synbody Biotechnology
Based in Connecticut, US, Synbody Biotechnology (SBI) is a start-up biotechnology company. IT is leveraging a revolutionary platform for the discovery and development of novel and attractive molecules in the therapeutic, diagnostic, and proteomic technology fields. Synbody technology is the first biopharmaceutical platform to capitalize on the recently recognized and important role of small flexible regions of proteins, termed molecular recognition features (MoRF), to mediate interactions with other proteins.
Who invested in Synbody Biotechnology
1 investor across 1 round
See all investors in Synbody Biotechnology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Mar 17, 2012
Amount
$0.8M
Investors
Questions about Synbody Biotechnology
Who invested in Synbody Biotechnology?
Synbody Biotechnology has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Synbody Biotechnology raised?
Synbody Biotechnology has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Synbody Biotechnology last raise money?
Synbody Biotechnology's most recent round on record is a Seed, in Mar 2012.
What does Synbody Biotechnology do?
Based in Connecticut, US, Synbody Biotechnology (SBI) is a start-up biotechnology company.
Where is Synbody Biotechnology headquartered?
Synbody Biotechnology is headquartered in Farmington, US.
Which VCs invest in companies like Synbody Biotechnology?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Synbody Biotechnology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Synbody Biotechnology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.